UnitedHealth shares are up significantly since I upgraded the stock to a buy rating.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA08 Oct 2025, 17:45 UTC
AI-generated source summary
The analyst discusses United Health stock, mentioning he previously rated it a buy between 270 and 235. The stock price has since increased to 359. He refers to Fiscal AI, noting the forward P/E ratio is now 22, up from lows of 13-14 earlier in 2025. He mentions that underperformance in 2025 was due to company estimate mistakes regarding the cost to serve their customers. He uses proprietary discounted cash flow valuations, with the model showing an intrinsic value of 449.17 per share. The analysis emphasizes a decade of free cash flow estimates and a weighted average cost of capital with the balance sheet. He still likes the risk reward profile at current market prices.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.